Procyon Advisors LLC Sells 82 Shares of Eli Lilly and Company (NYSE:LLY)

Procyon Advisors LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 2.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,523 shares of the company’s stock after selling 82 shares during the quarter. Procyon Advisors LLC’s holdings in Eli Lilly and Company were worth $3,116,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. Capital Planning LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth $6,916,000. M&G Plc purchased a new stake in Eli Lilly and Company during the first quarter valued at about $8,896,000. HighPoint Advisor Group LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $9,878,000. Finally, Leo Wealth LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $3,355,000. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LLY. Truist Financial lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Bank of America increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Barclays raised their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $979.29.

Eli Lilly and Company Trading Up 0.5 %

NYSE LLY opened at $936.61 on Monday. Eli Lilly and Company has a one year low of $547.61 and a one year high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market capitalization of $890.16 billion, a price-to-earnings ratio of 137.27, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company’s 50-day simple moving average is $910.84 and its two-hundred day simple moving average is $853.38.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Equities analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.